530 related articles for article (PubMed ID: 16455235)
1. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
2. A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon.
Kim H; Jeon H; Kong H; Yang Y; Choi B; Kim YM; Neckers L; Jung Y
Mol Pharmacol; 2006 Apr; 69(4):1405-12. PubMed ID: 16407467
[TBL] [Abstract][Full Text] [Related]
3. An anti-inflammatory mechanism of taurine conjugated 5-aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5-aminosalicylic acid on IL-1beta-mediated NFkappaB activation.
Joo K; Lee Y; Choi D; Han J; Hong S; Kim YM; Jung Y
Eur J Pharmacol; 2009 Sep; 618(1-3):91-7. PubMed ID: 19616541
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and properties of 5-aminosalicyl-taurine as a colon-specific prodrug of 5-aminosalicylic acid.
Jung YJ; Kim HH; Kong HS; Kim YM
Arch Pharm Res; 2003 Apr; 26(4):264-9. PubMed ID: 12735682
[TBL] [Abstract][Full Text] [Related]
5. N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats.
Mura C; Nácher A; Merino V; Merino-Sanjuan M; Carda C; Ruiz A; Manconi M; Loy G; Fadda AM; Diez-Sales O
Int J Pharm; 2011 Sep; 416(1):145-54. PubMed ID: 21723929
[TBL] [Abstract][Full Text] [Related]
6. 5-ASA-glutamate protects rats from inflammatory bowel disease induced by intracolonic administration of trinitrobenzensulfonic acid.
Clerici C; Gentili G; Pellicciari R; Gresele P; Mezzasoma AM; Giansanti M; Clementi M; Bartoli G; Balò S; Modesto R; Aburbeh AG; Morelli O; Morelli A
Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):385-90. PubMed ID: 9789134
[TBL] [Abstract][Full Text] [Related]
7. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
[TBL] [Abstract][Full Text] [Related]
8. N,N'-Bis(5-aminosalicyl)-L-cystine is a potential colon-specific 5-aminosalicylic acid prodrug with dual therapeutic effects in experimental colitis.
Kim H; Huh J; Jeon H; Choi D; Han J; Kim Y; Jung Y
J Pharm Sci; 2009 Jan; 98(1):159-68. PubMed ID: 18399548
[TBL] [Abstract][Full Text] [Related]
9. Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzenesulfonic acid-induced colitis in rats.
Dhaneshwar SS; Gairola N; Kandpal M; Vadnerkar G; Bhatt L
Bioorg Med Chem; 2007 Jul; 15(14):4903-9. PubMed ID: 17499512
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
Dhaneshwar SS; Kandpal M; Vadnerkar G; Rathi B; Kadam SS
Eur J Med Chem; 2007 Jun; 42(6):885-90. PubMed ID: 17258353
[TBL] [Abstract][Full Text] [Related]
11. Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats.
Tozaki H; Fujita T; Odoriba T; Terabe A; Okabe S; Muranishi S; Yamamoto A
J Pharm Pharmacol; 1999 Oct; 51(10):1107-12. PubMed ID: 10579681
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model.
Sawarkar SP; Deshpande SG; Bajaj AN; Nikam VS
AAPS PharmSciTech; 2015 Dec; 16(6):1445-54. PubMed ID: 26017284
[TBL] [Abstract][Full Text] [Related]
13. Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis.
Isozaki Y; Yoshida N; Kuroda M; Handa O; Takagi T; Kokura S; Ichikawa H; Naito Y; Okanoue T; Yoshikawa T
Scand J Gastroenterol; 2006 Aug; 41(8):944-53. PubMed ID: 16803693
[TBL] [Abstract][Full Text] [Related]
14. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid.
Jung YJ; Lee JS; Kim YM
J Pharm Sci; 2000 May; 89(5):594-602. PubMed ID: 10756325
[TBL] [Abstract][Full Text] [Related]
16. 5-Aminosalicylic Acid Azo-Linked to Procainamide Acts as an Anticolitic Mutual Prodrug via Additive Inhibition of Nuclear Factor kappaB.
Kim W; Nam J; Lee S; Jeong S; Jung Y
Mol Pharm; 2016 Jun; 13(6):2126-35. PubMed ID: 27112518
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon-specific delivery systems.
Zou M; Okamoto H; Cheng G; Hao X; Sun J; Cui F; Danjo K
Eur J Pharm Biopharm; 2005 Jan; 59(1):155-60. PubMed ID: 15567313
[TBL] [Abstract][Full Text] [Related]
18. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.
El-Kamel AH; Abdel-Aziz AA; Fatani AJ; El-Subbagh HI
Int J Pharm; 2008 Jun; 358(1-2):248-55. PubMed ID: 18502065
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
Dhaneshwar SS; Gairola N; Kandpal M; Vadnerkar G; Bhatt L; Rathi B; Kadam SS
Eur J Med Chem; 2009 Oct; 44(10):3922-9. PubMed ID: 19442419
[TBL] [Abstract][Full Text] [Related]
20. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
